Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 2/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.57 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | AHCY | P23526 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27432827 | 1.00 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL6045646 | 0.91 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL6045563 | 0.90 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL6045682 | 0.88 | ALDH1A1 (0.70) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL982442 | 0.84 | ALDH1A1 (0.76) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL8628392 | 0.84 | ALDH1A1 (0.64) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL12922453 | 0.83 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL12922451 | 0.81 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL6045664 | 0.81 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL11986907 | 0.81 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
| US-6887880-B2 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20020068745-A1 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002040481-A2 | ADENINE BASED INHIBITORS OF ADENYLYL CYCLASE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068745-A1 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | CD38, ADCY1, ADCY2 | ADORA2A 38/4885ADORA1 27/4885ADORA2B 52/4885 |
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | ADORA2A 303/4885ADORA1 398/4885ADORA2B 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.